Canada declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Archive — December 2025
Page 5 of 5 of this archive, newest first.
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 3 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The lowest effective dose is a real concept with almost no data behind it
The commonest real-world strategy in this drug class is the least studied one.
The named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
The out-of-range flag is a statistical convention with a printer attached
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
What a 21% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
PeptideMeter result on a Zhuhai tirzepatide lot lands 3.5 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.